Your browser doesn't support javascript.
From first to second wave: follow-up of the prospective Covid-19 cohort (KoCo19) in Munich (Germany)
Katja Radon; Abhishek Bakuli; Peter Puetz; Ronan Le Gleut; Jessica Michelle Guggenbuehl Noller; Laura Olbrich; Elmar Saathoff; Merce Gari; Yannik Schaelte; Turid Frahnow; Roman Woelfel; Michael Pritsch; Camilla Rothe; Michel Pletschette; Raquel Rubio-Acero; Jessica Beyerl; Dafni Metaxa; Felix Forster; Verena Thiel; Noemi Castelletti; Friedrich Riess; Maximilian N Diefenbach; Guenter Froeschl; Jan Marius Bruger; Simon Michael Winter; Jonathan Leon Frese; Kerstin Puchinger; Isabel Brand; Inge Kroidl; Andreas Wieser; Michael Hoelscher; Jan Hasenauer; Christiane Fuchs; - KoCo19 study group.
  • Katja Radon; LMU University Hospital Munich
  • Abhishek Bakuli; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
  • Peter Puetz; Institute of Computational Biology, Helmholtz Zentrum Muenchen - German Research Center for Environmental Health
  • Ronan Le Gleut; 5Institute of Computational Biology, Helmholtz Zentrum Muenchen - German Research Center for Environmental Health
  • Jessica Michelle Guggenbuehl Noller; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
  • Laura Olbrich; University Hospital, LMU Munich
  • Elmar Saathoff; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
  • Merce Gari; Helmholtz Zentrum for Environmental Health
  • Yannik Schaelte; Institute of Computational Biology, Helmholtz Zentrum Muenchen - German Research Center for Environmental Health
  • Turid Frahnow; Institute of Computational Biology, Helmholtz Zentrum Muenchen - German Research Center for Environmental Health
  • Roman Woelfel; Bundeswehr Institute of Microbiology, Munich
  • Michael Pritsch; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Camilla Rothe; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Michel Pletschette; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Raquel Rubio-Acero; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Jessica Beyerl; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Dafni Metaxa; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Felix Forster; Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich
  • Verena Thiel; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Noemi Castelletti; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Friedrich Riess; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Maximilian N Diefenbach; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Guenter Froeschl; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Jan Marius Bruger; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Simon Michael Winter; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Jonathan Leon Frese; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Kerstin Puchinger; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Isabel Brand; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Inge Kroidl; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Andreas Wieser; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Michael Hoelscher; Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich
  • Jan Hasenauer; University of Bonn
  • Christiane Fuchs; Institute of Computational Biology, Helmholtz Zentrum Muenchen - German Research Center for Environmental Health
  • - KoCo19 study group;
Preprint in English | medRxiv | ID: ppmedrxiv-21256133
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
BackgroundIn the 2nd year of the Covid-19 pandemic, knowledge about the dynamics of the infection in the general population is still limited. Such information is essential for health planners, as many of those infected show no or only mild symptoms and thus, escape the surveillance system. We therefore aimed to describe the course of the pandemic in the Munich general population living in private households from April 2020 to January 2021. MethodsThe KoCo19 baseline study took place from April to June 2020 including 5313 participants (age 14 years and above). From November 2020 to January 2021, we could again measure SARS-CoV-2 antibody status in 4,433 of the baseline participants (response 83%). Participants were offered a self-sampling kit to take a capillary blood sample (dry blood spot; DBS). Blood was analysed using the Elecsys(R) Anti-SARS-CoV-2 assay (Roche). Questionnaire information on socio-demographics and potential risk factors assessed at baseline was available for all participants. In addition, follow-up information on health-risk taking behaviour and number of personal contacts outside the household (N=2768) as well as leisure time activities (N=1263) were collected in summer 2020. ResultsWeighted and adjusted (for specificity and sensitivity) SARS-CoV-2 sero-prevalence at follow-up was 3.6% (95% CI 2.9-4.3%) as compared to 1.8% (95% CI 1.3-3.4%) at baseline. 91% of those tested positive at baseline were also antibody-positive at follow-up. While sero-prevalence increased from early November 2021 to January 2021, no indication of geospatial clustering across the city of Munich was found, although cases clustered within households. Taking baseline result and time to follow-up into account, men and participants in the age group 20-34 years were at the highest risk of sero-positivity. In the sensitivity analyses, differences in health-risk taking behaviour, number of personal contacts and leisure time activities partly explained these differences. ConclusionThe number of citizens in Munich with SARS-CoV-2 antibodies was still below 5% during the 2nd wave of the pandemic. Antibodies remained present in the majority of baseline participants. Besides age and sex, potentially confounded by differences in behaviour, no major risk factors could be identified. Non-pharmaceutical public health measures are thus still important.
Full text: Available Collection: Preprints Database: medRxiv Type of study: Observational study / Prognostic study / Risk factors Language: English Year: 2021 Document Type: Preprint

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Collection: Preprints Database: medRxiv Type of study: Observational study / Prognostic study / Risk factors Language: English Year: 2021 Document Type: Preprint